A

Alexion

Global biopharmaceuticals focusing on rare diseases

Medical Writer Intern

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
InternshipBoston, MA, USA$41 - $48 /hr

About the Job

Requirements

  • Currently pursuing a PhD or a non-MBA Master's degree in Public Health, Pharmaceutical Science, Regulatory Science, or Biological Science.
  • Meet the applicable graduation timeline requirement, with an anticipated graduation date after August 2027.
  • Have U.S. work authorization at the time of application that does not require future sponsorship; OPT support will not be provided.
  • Have advanced proficiency with Microsoft Word functions.
  • Have strong writing and editing ability, including the ability to summarize data.
  • Have scientific or technical understanding.
  • Have critical-thinking and analytical skills.
  • Have strong communication and presentation skills.
  • Be able to report on site to Boston-Seaport, Massachusetts, 3 days a week.

Responsibilities

  • Co-author clinical-regulatory documents within a program, ensuring relevant regulatory, technical, and quality standards are achieved.
  • Apply relevant processes and best practices to the development of clinical-regulatory documents.
  • Contribute to AI-based Medical Writing initiatives that facilitate the automation of content or tasks for process improvement.
  • Interpret complex clinical data and information and condense it into clear, concise, and accurate messages that address information requirements.

Desired Qualifications

  • Experience with electronic document management systems is a plus.
  • Experience with AI-assisted drafting and summarization tools is a plus.

About the Company

Alexion

Global biopharmaceuticals focusing on rare diseases

Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Boston, MA
Founded
1992

Recently Posted Jobs

Explore more opportunities at Alexion

See more jobs